76 unknown. 76 Phase 1, 28 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 76 | Unknown 76 |
| Phase 2 | 28 | Unknown 28 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Utility and Safety of Human Umbilical Cord Mesenchymal Stem Cell Secretome in Moderate Neurocognitive Impairment (Dementia) Secretome injection, Vitamin B12 Injection - Dementia, Moderate Dementia | Phase 1 | Unknown | Baermed | 54 | 2024-10-15 | 2024-10-09 |
| Ketofol Versus Dexmedetomidine for Prevention of Emergence Delirium in Pediatric Patients Undergoing Squint Surgeries Ketamine, Dexmedetomidine - Emergence Delirium | Phase 1 / Phase 2 | Unknown | Cairo University | 46 | 2024-08-10 | 2024-08-20 |
| A Single Dose Escalation Study of HHT201 in Healthy Subjects Donepezil Dihydroxynaphthalate for Injection - Alzheimer Disease | Phase 1 | Unknown | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | 64 | 2024-06-01 | 2024-04-18 |
| Single Dose Escalation Study of CM383 in Healthy Volunteers CM383, Placebo - Alzheimer Disease | Phase 1 | Unknown | Keymed Biosciences Co.Ltd | 56 | 2024-05-28 | 2024-11-08 |
| Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke Pentoxifylline - Cognitive Impairment | Phase 1 / Phase 2 | Unknown | The First Hospital of Hebei Medical University | 200 | 2024-04-10 | 2024-04-03 |
| A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People DDN-A-0101 (SAD), DDN-A-0101 (MAD), Placebo (SAD) - Alzheimer Disease | Phase 1 | Unknown | Pharmacobio | 100 | 2024-04-01 | 2024-04-16 |
| A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's BMS-9894923 - Parkinson Disease | Phase 1 | Unknown | Allyx Therapeutics | 18 | 2024-03-15 | 2024-03-18 |
| Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care Dexmedetomidine Hydrochloride - Hyperactive Delirium, Delirium of Mixed Origin | Phase 1 / Phase 2 | Unknown | Bruyère Health Research Institute. | 50 | 2024-01-30 | 2025-04-15 |
| Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers GB-5001A, GB-5001D, Oral cohort - Alzheimer Disease | Phase 1 | Unknown | G2GBio, Inc. | 56 | 2024-01-03 | 2023-12-22 |
| Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS). VIX001 - Post-Acute COVID-19 Syndrome, Cognitive Impairment | Phase 1 | Unknown | Neobiosis, LLC | 9 | 2023-10-01 | 2023-07-17 |
| Dexmedetomidine Versus Ketamine Versus Magnesium Sulfate for the Prevention of Emergence Agitation Following Sevoflurane Induced Anesthesia in Cardiac Catheterization in Pediatrics Dexmedetomidine, Ketamine, Magnesium - Anesthesia Emergence Delirium | Phase 1 / Phase 2 | Unknown | Cairo University | 100 | 2023-09-20 | 2023-10-11 |
| Evaluate Tolerability and Safety of HY209 in Healthy Volunteers HY-209, HY-209 placebo - Dementia | Phase 1 | Unknown | Kukjeon Pharmaceutical Co.,Ltd. | 59 | 2023-09-13 | 2024-08-15 |
| Tdap and Biomarkers of Alzheimer's Disease tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine - Alzheimer Disease, Late Onset | Phase 1 / Phase 2 | Unknown | Mindful Diagnostics and Therapeutics, LLC | 50 | 2023-05-01 | 2022-08-25 |
| Protecting Alzheimer Caregivers Using Technology Through Staying Sharp Staying Sharp intervention - Mild Cognitive Impairment, Dementia Alzheimers | Phase 1 / Phase 2 | Unknown | Oregon Health and Science University | 138 | 2023-04-30 | 2023-02-09 |
| Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery Dexmedetomidine Injection, Ropivacaine and Dexmedetomidine, Sodium Chloride Injection - Dexmedetomidine, Fascia Iliaca Block | Phase 1 | Unknown | Qianfoshan Hospital | 207 | 2023-02-05 | 2024-09-26 |
| Tau And Connectomics In TES Study [18F] PI-2620 Tau Ligand - Chronic Traumatic Encephalopathy, Traumatic Encephalopathy | Phase 1 | Unknown | Macquarie University, Australia | 12 | 2023-02-03 | 2024-02-28 |
| Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers BMS-984923 - Alzheimer Disease, Dementia | Phase 1 | Unknown | Allyx Therapeutics | 12 | 2023-01-10 | 2024-07-30 |
| Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19 CCT Long COVID - Post-Acute COVID-19, Post Acute COVID-19 Syndrome | Phase 1 / Phase 2 | Unknown | Universidad Antonio de Nebrija | 20 | 2022-10-18 | 2022-10-18 |
| Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors Vitamin D - Gastrointestinal Neoplasms, Cognitive Impairment | Phase 1 / Phase 2 | Unknown | Yangzhou University | 114 | 2022-09-22 | 2022-09-23 |
| A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants APNmAb005, Placebo - Healthy Volunteers, Tauopathies | Phase 1 | Unknown | APRINOIA Therapeutics, LLC | 40 | 2022-05-06 | 2023-06-15 |
Showing 20 of 76. Sign in to see all of them.
Alzheimer Disease (32) · Cognitive Dysfunction (23) · Dementia (10) · Huntington Disease (7) · Emergence Delirium (5) · Pick Disease of the Brain (4) · Dementia, Vascular (3) · Brain Injuries, Traumatic (2) · COVID-19 (2) · Chorea (2) · Cognition Disorders (2) · Consciousness Disorders (2) · Memory Disorders (2) · Neurodegenerative Diseases (2) · Parkinson Disease (2)
Mental Disorders (76) · Nervous System Diseases (63) · Brain Diseases (53) · Central Nervous System Diseases (53) · Dementia (41) · Neurodegenerative Diseases (41) · Tauopathies (31) · Cognition Disorders (30) · Pathological Conditions, Signs and Symptoms (19) · Signs and Symptoms (15) · Neurologic Manifestations (14) · Neurobehavioral Manifestations (12) · Basal Ganglia Diseases (10) · Movement Disorders (10)
Dexmedetomidine (6) · Ketamine (2) · Nalbuphine (2) · Sodium Chloride (2) · Vitamin B 12 (2) · AADvac1 (1) · Bupivacaine (1) · CKD-504 (1) · Cell- and Tissue-Based Therapy (1) · Cholecalciferol (1) · Cohort Studies (1) · Donepezil (1) · Emtricitabine (1) · Flumazenil (1) · Folic Acid (1)
GAAD Medical Research Institute Inc. (4) · Allyx Therapeutics (2) · Cairo University (2) · National Institute on Aging (NIA) (2) · Oregon Health and Science University (2) · VTBIO Co. LTD (2) · APRINOIA Therapeutics, LLC (1) · Adeona Pharmaceuticals (1) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Ain Shams University (1) · American Society Of Thermalism And Climatology Inc (1) · Assaf-Harofeh Medical Center (1) · Assiut University (1) · Axon Neuroscience SE (1) · Azidus Brasil (1)
United States (21) · China (9) · Canada (7) · South Korea (6) · Egypt (4) · Israel (4) · Australia (2) · Brazil (2) · Iran (2) · Netherlands (2) · Colombia (1) · France (1) · Germany (1) · India (1) · Indonesia (1)
Ken Nedd, M.D. (4) · Kwasi Donyina, Ph.D. (2) · A. M. Barrett, MD (1) · Amany Saleh, MD (1) · Bin Zhang, M.D. Ph.D. (1) · Chao-Yi Wu, PhD (1) · Coad T Dow, MD (1) · Daorong Wang, Professor (1) · David Newsome, M.D. (1) · Dongqing Lv (1) · Dongsheng Fan, M.D. (1) · Elissa Ash, Dr. (1) · Fontaine Denys, PhD (1) · Gang Wang, MD,PhD (1)
PMID 22136481, PMID 22655593, PMID 26136594, PMID 26774115, PMID 27389402, PMID 27434297, PMID 30341095, PMID 32375872, PMID 33933117, PMID 34670118, PMID 35704085, PMID 36170815, PMID 36905458, PMID 37859748, PMID 38690718, PMID 39626378, PMID 39760921, PMID 40235521, PMID 40368603, PMID 41188963, PMID 42791030
2017 (1), P30AG024978 (1), R01AG022462 (1), R01AG024010 (1), R43AG060851 (1)